![]() |
![]() |
Teisinis statusas
Patentas neįsigaliojo (pagal Susitarimą)
(51) | INT.CL. | C07D 207/34 | |
A61K 31/40 | |||
A61P 3/06 | |||
A61P 25/28 |
(11) | Patento numeris | 1423364 |
(13) | Dokumento rūšis | T |
(96) | Europos patento paraiškos numeris | 02727946.2 |
Europos patento paraiškos padavimo data | 2002-05-21 | |
(97) | Europos patento paraiškos paskelbimo data | 2004-06-02 |
(45) | Paskelbimo apie Europos patento išdavimą data | 2015-11-04 |
(46) | Apibrėžties vertimo paskelbimo data |
(86) | Numeris | PCT/IB2002/001796 |
Data | 2002-05-21 |
(87) | Numeris | WO 2003/004470 |
Data | 2003-01-16 |
(30) | Numeris | Data | Šalis |
302049 P | 2001-06-29 | US |
(72) |
BYRN, Stephen Robert, US
COATES, David Andrew, US
GUSHURST, Karen Sue, US
MORRISON, Henry Grant, II, US
PARK, Aeri, US
VLAHOVA, Petinka Ivanova, US
LI, Zheng J., Pfizer Global Research and Develop., US
KRZYZANIAK, J. F., Pfizer Global Researchand Dev., US
|
(73) |
Warner-Lambert Company LLC,
235 East 42nd Street, New York, NY 10017,
US
|
(54) | CRYSTALLINE FORMS OF [R-(R*,R*)]-2-(4-FLUOROPHENYL)-BETA, DELTA-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-PHENYLAMINO)CARBONYL]-1H-PYRROLE-1-HEPTANOIC ACID CALCIUM SALT (2:1) (ATORVASTATIN) |
CRYSTALLINE FORMS OF [R-(R*,R*)]-2-(4-FLUOROPHENYL)-BETA, DELTA-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-PHENYLAMINO)CARBONYL]-1H-PYRROLE-1-HEPTANOIC ACID CALCIUM SALT (2:1) (ATORVASTATIN) |